Is acute promyelocytic leukemia a curable disease? Treatment strategy for a long-term survival.

abstract：:Histone deacetylase (HDAC) inhibitors, which are approved for the treatment of cutaneous T-cell lymphoma and multiple myeloma, are undergoing evaluation in other lymphoid neoplasms. How they kill susceptible cells is incompletely understood. Here, we show that trichostatin A, romidepsin and panobinostat induce apoptos...

journal_title：Leukemia

authors： Ding H,Peterson KL,Correia C,Koh B,Schneider PA,Nowakowski GS,Kaufmann SH

更新日期：2017-07-01 00:00:00

abstract：:We have investigated the activity of ITF2357, a novel hydroxamate histone deacetylase inhibitor, on multiple myeloma (MM) and acute myelogenous leukemia (AML) cells in vitro and in vivo. ITF2357 induced apoptosis in 8/9 MM and 6/7 AML cell lines, as well as 4/4 MM and 18/20 AML freshly isolated cases, with a mean IC(5...

journal_title：Leukemia

authors： Golay J,Cuppini L,Leoni F,Micò C,Barbui V,Domenghini M,Lombardi L,Neri A,Barbui AM,Salvi A,Pozzi P,Porro G,Pagani P,Fossati G,Mascagni P,Introna M,Rambaldi A

更新日期：2007-09-01 00:00:00

abstract：:Feline sarcoma virus of Snyder-Theilen strain (ST-FeSV) induces sarcomas in Wistar/Ma rats following neonatal virus injection. Induced tumors express the viral oncogene product (P85) and elicit in hosts the specific serum anti-P85 antibody detectable by Western blot analysis. Syngeneic adult female rats were immunized...

journal_title：Leukemia

authors： Maruyama K,Miyauchi M,Mochizuki S,Fukushima T,Koshikawa N,Kawamura K,Awaya A,Kobayashi H

更新日期：1994-04-01 00:00:00

abstract：:The myeloproliferative neoplasms (MPNs) are characterized by hematopoietic stem/progenitor cell (HSPC) expansion and overproduction of mature blood cells. The JAK2V617F mutation is present in hematopoietic cells in a majority of patients with MPNs, but the mechanism(s) responsible for MPN stem cell expansion remain in...

journal_title：Leukemia

authors： Zhan H,Ma Y,Lin CH,Kaushansky K

更新日期：2016-12-01 00:00:00

abstract：:We have investigated the effects of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] and several potent vitamin D3 analogs [1,25(OH)2-16-ene-23-yne-D3; 1,25(OH)2-16-ene-23-yne-26,27-F6-D3] on productive infection by human immunodeficiency virus (HIV) in human macrophages. Macrophages derived from the peripheral blood were eithe...

journal_title：Leukemia

authors： Kizaki M,Ikeda Y,Simon KJ,Nanjo M,Koeffler HP

更新日期：1993-10-01 00:00:00

abstract：:Some anaplastic large cell lymphomas (ALCLs) carry a specific chromosomal translocation, t(2;5)(p23;q35). Recently, we found a novel hyperphosphorylated 80-kDa protein tyrosine kinase, p80, in ALCLs with t(2;5). Subsequent cDNA cloning revealed p80 to be a fusion protein of two genes, the novel tyrosine kinase gene an...

journal_title：Leukemia

authors： Shiota M,Mori S

更新日期：1997-04-01 00:00:00

abstract：:Identification of rearrangements in the immunoglobulin heavy chain (IgH), T cell receptor (TCR) and other genes assists in the classification of hemopoietic disorders. This study reviews a 5 year experience of genotyping as an assessment of clonality in a central referral laboratory. Patients were referred for assessm...

journal_title：Leukemia

authors： Rockman SP

更新日期：1997-06-01 00:00:00

abstract：:Bryostatin 1 is a macrocyclic lactone activator of protein kinase C which has displayed promising antileukemic potential in pre-clinical studies. We have assessed the effect of bryostatin 1 on the in vitro clonogenic response of leukemic myeloblasts obtained from 12 patients with acute non-lymphocytic leukemia to reco...

journal_title：Leukemia

authors： Grant S,Pettit GR,Howe C,McCrady C

更新日期：1991-05-01 00:00:00

abstract：:Response rates of 20% were achieved when interferon alpha (IFN) was applied as single agent treatment for multiple myeloma. A synergistic activity was observed when IFN was combined with chemotherapeutic agents in vitro and in vivo. These observations led to a series of randomized trials comparing chemotherapy alone w...

journal_title：Leukemia

authors： Gisslinger H

更新日期：1997-12-01 00:00:00

abstract：:Improved survival of patients with acute lymphoblastic leukemia (ALL) has emerged from identifying new prognostic markers; however, 20% of children still suffer recurrence. Previously, the altered expression of Fat1 cadherin has been implicated in a number of solid tumors. In this report, in vitro analysis shows that ...

journal_title：Leukemia

authors： de Bock CE,Ardjmand A,Molloy TJ,Bone SM,Johnstone D,Campbell DM,Shipman KL,Yeadon TM,Holst J,Spanevello MD,Nelmes G,Catchpoole DR,Lincz LF,Boyd AW,Burns GF,Thorne RF

更新日期：2012-05-01 00:00:00

abstract：:The INK4A/ARF locus yields two tumor suppressors, p16INK4A and p14ARF, and is frequently deleted in human tumors. We studied their mRNA expressions in 41 hematopoietic cell lines and in 137 patients with hematological malignancies; we used a quantitative reverse transcription-PCR assay. Normal peripheral bloods, bone ...

journal_title：Leukemia

authors： Taniguchi T,Chikatsu N,Takahashi S,Fujita A,Uchimaru K,Asano S,Fujita T,Motokura T

更新日期：1999-11-01 00:00:00

abstract：:C-mpl ligand acts primarily as a lineage-specific hematopoietic growth factor by promoting proliferation of megakaryocyte precursors and their differentiation into megakaryocytes and platelets. In addition to the ability of c-mpl ligand to support megakaryocytic development from CD34+ precursor cells, several lines of...

journal_title：Leukemia

authors： Hofmann WK,Ottmann OG,Hoelzer D

更新日期：1999-01-01 00:00:00

abstract：:Of 240 Japanese children with acute lymphoblastic leukemia (ALL) treated between 1983 and 1990, 75 (31%) had normal diploidy, 47 (20%) hyperdiploidy with more than 50 chromosomes, 18 (8%) hyperdiploidy with 47-50 chromosomes, 77 (32%) pseudodiploidy, 22 (9%) hypodiploidy and one hypotetraploidy in the leukemic cells. ...

journal_title：Leukemia

authors： Kobayashi H,Maseki N,Homma C,Sakurai M,Kaneko Y

更新日期：1994-11-01 00:00:00

abstract：:Autoradiographic analysis of the binding of radiolabeled murine IL-6 to murine cells revealed that blast cells, megakaryocytic and monocytic cells in the marrow expressed receptors but not erythroid, eosinophilic or neutrophilic granulocytic cells. In the thymus, spleen and lymph nodes, most cells expressing receptors...

journal_title：Leukemia

authors： McKinstry W,Metcalf D,Li CL

更新日期：1994-10-01 00:00:00

abstract：:Large granular lymphocyte leukemia (LGLL) is a rare and chronic lymphoproliferative disorder characterized by the clonal expansion of LGLs. LGLL patients can be asymptomatic or develop cytopenia, mostly neutropenia. Somatic STAT3 and STAT5b mutations have been recently reported in approximately 40% of patients. The ai...

journal_title：Leukemia

authors： Barilà G,Teramo A,Calabretto G,Vicenzetto C,Gasparini VR,Pavan L,Leoncin M,Vedovato S,Frigo AC,Facco M,Semenzato G,Zambello R

更新日期：2020-04-01 00:00:00

abstract：:We explored the association between bone marrow plasma cells (BMPCs) and disease presentation and outcome among 1574 AL patients. Three BMPC groups were formulated: <5% (n = 231, 15% of study population), 5-19% (n = 1045, 66%), and ≥20% (n = 298, 19%). Heart and renal involvement were more and less prevalent, respecti...

journal_title：Leukemia

authors： Muchtar E,Gertz MA,Kourelis TV,Sidana S,Go RS,Lacy MQ,Buadi FK,Dingli D,Hayman SR,Kapoor P,Leung N,Fonder A,Hobbs M,Lisa Hwa Y,Gonsalves W,Warsame R,Russell S,Lust JA,Lin Y,Zeldenrust S,Rajkumar SV,Kyle RA,Kum

更新日期：2020-04-01 00:00:00

abstract：:Myeloproliferative neoplasms with myelofibrosis (MPN-MF) demonstrate constitutive activation of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling that responds to treatment with the JAK1 and 2 kinase inhibitor (JAKi) ruxolitinib. However, MPN-MF often progresses (~20%) to secondary acu...

journal_title：Leukemia

authors： Saenz DT,Fiskus W,Manshouri T,Rajapakshe K,Krieger S,Sun B,Mill CP,DiNardo C,Pemmaraju N,Kadia T,Parmar S,Sharma S,Coarfa C,Qiu P,Verstovsek S,Bhalla KN

更新日期：2017-03-01 00:00:00

abstract：:The International Acute Lymphoblastic Leukemia Working Group, the so-called 'Ponte di Legno Workshop' has led to substantial progress in international collaboration in leukemia research. On April 27-28, 2005, the 8th Meeting was held in Vienna, Austria, to continue the discussions about special common treatment elemen...

journal_title：Leukemia

authors： Gadner H,Masera G,Schrappe M,Eden T,Benoit Y,Harrison C,Nachman J,Pui CH

更新日期：2006-01-01 00:00:00

abstract：:The current study was initiated to compare the anti-lymphoma activity and side-effects of prednimustine/mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) in patients with advanced low-grade non-Hodgkin's lymphomas in way of a prospective randomized multicenter trial. Two hundred and forty-six patie...

journal_title：Leukemia

authors： Unterhalt M,Herrmann R,Tiemann M,Parwaresch R,Stein H,Trümper L,Nahler M,Reuss-Borst M,Tirier C,Neubauer A,Freund M,Kreuser ED,Dietzfelbinger H,Bodenstein H,Engert A,Stauder R,Eimermacher H,Landys K,Hiddemann W

更新日期：1996-05-01 00:00:00

abstract：:The standard paradigm of embryologic development and adult tissue reconstitution posits unidirectional, hierarchical lineages. The presumed mechanisms underlying these differentiative pathways are gene restrictions, such as methylation and heterochromatin formation, which are commonly described as irreversible. Howeve...

journal_title：Leukemia

authors： Theise ND,Krause DS

更新日期：2002-04-01 00:00:00

abstract：:JAK2V617F is the most common mutation in patients with BCR-ABL negative myeloproliferative neoplasms (MPNs). The eradication of JAK2V617F hematopoietic stem cells (HSCs) is critical for achieving molecular remissions and cure. We investigate the distinct effects of two therapies, ruxolitinib (JAK1/2 inhibitor) and int...

journal_title：Leukemia

authors： Austin RJ,Straube J,Bruedigam C,Pali G,Jacquelin S,Vu T,Green J,Gräsel J,Lansink L,Cooper L,Lee SJ,Chen NT,Lee CW,Haque A,Heidel FH,D'Andrea R,Hill GR,Mullally A,Milsom MD,Bywater M,Lane SW

更新日期：2020-04-01 00:00:00

abstract：:Bruton's tyrosine kinase (BTK) inhibitor is a promising novel agent that has potential efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new drug approval. The first-in-class drug ibrutinib creates possibilities for an era of chemotherapy-free management of B-cell malignancies,...

journal_title：Leukemia

authors： Wen T,Wang J,Shi Y,Qian H,Liu P

更新日期：2020-10-29 00:00:00

abstract：:Inhibition of NOTCH1 signaling with gamma-secretase inhibitors (GSIs) has been proposed as a molecularly targeted therapy in T-cell acute lymphoblastic leukemia (T-ALL). However, GSIs seem to have limited antileukemic activity in human T-ALL and are associated with severe gastrointestinal toxicity resulting from inhib...

journal_title：Leukemia

authors： Real PJ,Ferrando AA

更新日期：2009-08-01 00:00:00

abstract：:The introduction of BCR-ABL tyrosine kinase inhibitors has revolutionized the treatment of chronic myeloid leukemia (CML). A major clinical aim remains the identification and elimination of low-level disease persistence, termed "minimal residual disease". The phenomenon of disease persistence suggests that despite tar...

journal_title：Leukemia

authors： Kinstrie R,Horne GA,Morrison H,Irvine D,Munje C,Castañeda EG,Moka HA,Dunn K,Cassels JE,Parry N,Clarke CJ,Scott MT,Clark RE,Holyoake TL,Wheadon H,Copland M

更新日期：2020-06-01 00:00:00

abstract：:Minimal residual disease (MRD) is a powerful prognostic factor in acute lymphoblastic leukemia (ALL) and is used for patient stratification and treatment decisions, but its precise role in Philadelphia chromosome positive ALL is less clear. This uncertainty results largely from methodological differences relating to t...

journal_title：Leukemia

authors： Pfeifer H,Cazzaniga G,van der Velden VHJ,Cayuela JM,Schäfer B,Spinelli O,Akiki S,Avigad S,Bendit I,Borg K,Cavé H,Elia L,Reshmi SC,Gerrard G,Hayette S,Hermanson M,Juh A,Jurcek T,Chillón MC,Homburg C,Martinelli G,

更新日期：2019-08-01 00:00:00

abstract：:NUP98 gene rearrangements occur in acute myeloid leukemia and result in the expression of fusion proteins. One of the most frequent is NUP98-DDX10 that fuses a portion of NUP98 to a portion of DDX10, a putative DEAD-box RNA helicase. Here, we show that NUP98-DDX10 dramatically increases proliferation and self-renewal ...

journal_title：Leukemia

authors： Yassin ER,Abdul-Nabi AM,Takeda A,Yaseen NR

更新日期：2010-05-01 00:00:00

abstract：:We have investigated the involvement of tumor suppressor genes (p53 and RB1) and dominantly acting oncogenes (Ras family genes) in BCR/ABL positive and negative chronic myeloproliferative disorders (CMPD) at different stages of the disease, including 26 cases of BCR/ABL+ chronic myeloid leukemia (CML) blast crisis, 9 ...

journal_title：Leukemia

authors： Gaidano G,Guerrasio A,Serra A,Rege-Cambrin G,Saglio G

更新日期：1994-04-01 00:00:00

abstract：:Fas ligand (FasL) is capable of inducing apoptosis of lymphoid cells by cross-linking with its natural receptor, Fas. We aimed to investigate the possible role of the Fas/FasL-mediated apoptosis in the development of human lymphomas. FasL mRNA was detected by reverse transcriptase-polymerase chain reaction in 38 out o...

journal_title：Leukemia

authors： Xerri L,Devilard E,Hassoun J,Haddad P,Birg F

更新日期：1997-11-01 00:00:00

abstract：:Cyclooxygenase (COX)-1 or -2 and specific prostaglandin (PG) synthases catalyze the formation of various PGs. We investigated the expression and activity of COX-1 and -2 during granulocyte-oriented maturation induced by all-trans-retinoic acid (ATRA) of NB4 cells, originated from a human acute promyelocytic leukemia (...

journal_title：Leukemia

authors： Rocca B,Morosetti R,Habib A,Maggiano N,Zassadowski F,Ciabattoni G,Chomienne C,Papp B,Ranelletti FO

更新日期：2004-08-01 00:00:00

abstract：:Transplantation of normal and malignant human hematopoietic cells into severe combined immunodeficient (SCID) mice allows for evaluation of long-term growth abilities of these cells and provides a preclinical model for therapeutic interventions. However, large numbers of cells are required for successful engraftment i...

journal_title：Leukemia

authors： Terpstra W,Leenen PJ,van den Bos C,Prins A,Loenen WA,Verstegen MM,van Wyngaardt S,van Rooijen N,Wognum AW,Wagemaker G,Wielenga JJ,Löwenberg B

更新日期：1997-07-01 00:00:00